GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Quality Rank

Lantern Pharma (Lantern Pharma) Quality Rank


View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Lantern Pharma Quality Rank Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantern Pharma (Lantern Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Quality Rank
Comparable Companies
NERV UBX ALGS LUMO NRXP MAIA SEEL NLTX SIOX MTEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Website
https://www.lanternpharma.com
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini director 1223 FOXGLOVE LANE, WEST CHESTER PA 19380